There is only 1 RCT on intensi ed BP control in kidney transplant recipients that compared to standard blood pressure (MAP between 50th and 99th percentiles) versus intensi ed BP control (MAP <50th percentile), and it did not report on any clinical outcomes.298 The Work Group judged that a target of <130 mm Hg systolic, using standardized of ce measurement, remained a reasonable goal for kidney transplant recipients. A higher target SBP, such as 140 mm Hg, was in the opinion of the Work Group too high given the preponderance of evidence from RCTs demonstrating survival and CV bene ts of tar- geting SBP <130 mm Hg in the general population.299 301 In contrast, the Work Group judged that a lower SBP goal, such as 120 mm Hg (see Recommendation 3.1.1), may not be appropriate for kidney transplant recipients without further data on the risks and bene ts of targeting this level of BP in this population. This concern for the lower SBP goal of <120 mm Hg partly stems from observations from the SPRINT trial showing that, compared to the standard arm (SBP target <140 mm Hg), patients in the intensive BP arm had modestly higher rates of eGFR decline within the 3-year follow-up of the trial,91,302 AKI (albeit mild in in- and incident CKD,134 which may be of concern to kidney transplant recipients and clinicians (see Values and preferences below). It is conceivable that kidney trans- plant patients with a solitary, denervated kidney could be at an even higher risk for such adverse events with intensive BP lowering, although this has not been substantiated by clinical data. Data from RCTs involving kidney transplant recipients will be needed to provide a clearer pro le of the true risks and bene ts of a SPRINT-like goal in this population. 